Table 3.
Epidemiology | Type of lesion | Mechanism | |
Typical | |||
Cloropromazine | Jaundice: 0.16%-0.3%[99] Severe DILI: > 350[100,101,115-124] Fatal Injury: 8[102-109] | Cholestatic | Immuno-allergic |
Haloperidol | ALT > 3ULN: 2%[110] Severe DILI: 1[111] | Cholestatic | Immuno-allergic |
Atypical | |||
Clozapine | ALT > 3ULN: 15%[125] Severe DILI: 16[126-140] Fatal Injury: 2[141,142] | Hepatocellular Cholestatic Chronic esteatosis | Immuno-allergic Chronic estatosis |
Olanzapine | ALT > 3ULN: 6%[143] Severe DILI: 7[139,144-149] | Hepatocellular Cholestatic Chronic esteatosis | Immuno-allergic, Chronic estatosis |
Risperidone | ALT > 3ULN: 3%[150] Severe DILI: 13[150-162] | Hepatocellular Cholestatic Chronic esteatosis | Immuno-allergic Chronic estatosis |
Quetiapine | ALT > 3ULN: 0%[143] Severe DILI: 3[151,163,164] Fatal injury: 2[165,166] | ? | ? |
Ziprasidone | Not reported Severe DILI: 1[167] | ? | ? |
Aripiprazole | Not reported | ||
Amissulpride | Not reported |
DILI: Drug-induced liver injury; ALT: Alanine aminotransferase; ULN: Upper normal limit.